Elevance Health, Inc. $ELV Shares Purchased by ProVise Management Group LLC

ProVise Management Group LLC boosted its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 11.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,275 shares of the company’s stock after purchasing an additional 3,094 shares during the period. ProVise Management Group LLC’s holdings in Elevance Health were worth $11,383,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ELV. Field & Main Bank boosted its position in shares of Elevance Health by 1.3% during the second quarter. Field & Main Bank now owns 1,883 shares of the company’s stock worth $728,000 after buying an additional 25 shares during the period. Simplicity Wealth LLC grew its holdings in shares of Elevance Health by 1.3% during the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company’s stock worth $754,000 after buying an additional 25 shares in the last quarter. Tranquilli Financial Advisor LLC grew its holdings in shares of Elevance Health by 1.3% during the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock worth $805,000 after buying an additional 26 shares in the last quarter. Mather Group LLC. raised its position in Elevance Health by 3.5% in the 3rd quarter. Mather Group LLC. now owns 766 shares of the company’s stock valued at $298,000 after buying an additional 26 shares during the last quarter. Finally, 55 North Private Wealth LLC raised its position in Elevance Health by 4.5% in the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock valued at $233,000 after buying an additional 26 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Buying and Selling at Elevance Health

In related news, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares in the company, valued at approximately $6,533,560. The trade was a 8.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is currently owned by company insiders.

Elevance Health Price Performance

Shares of NYSE ELV opened at $429.50 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The business has a 50-day moving average of $415.40 and a 200-day moving average of $375.20. The stock has a market capitalization of $92.80 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.05 and a beta of 0.63. Elevance Health, Inc. has a fifty-two week low of $274.84 and a fifty-two week high of $450.69.

Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same quarter in the prior year, the company posted $6.03 earnings per share. Elevance Health’s revenue was up .7% on a year-over-year basis. As a group, sell-side analysts predict that Elevance Health, Inc. will post 29.15 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s dividend payout ratio is presently 29.34%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ELV shares. Royal Bank Of Canada boosted their target price on Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research note on Thursday, October 22nd. Morgan Stanley raised their price target on shares of Elevance Health from $404.00 to $449.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 22nd. TD Cowen lifted their price objective on shares of Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a report on Friday, October 23rd. Wall Street Zen upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, Robert W. Baird boosted their price objective on shares of Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Fifteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $456.48.

Check Out Our Latest Stock Analysis on ELV

Elevance Health Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Featured Articles

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.